Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519164 · ClinicalTrials.gov registry record · Phase 4
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT04519164 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 79 participants.
The verdict
NCT04519164, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis, independent of blood pressure, and proportionately to the severity of autonomous aldosterone production.
Interventions
- DRUG Eplerenone
- DRUG Chlorthalidone with potassium chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-09-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04519164
The ClinicalTrials.gov registry entry for NCT04519164 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eplerenone is the first listed.
NCT04519164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04519164 about?
NCT04519164 is a clinical study titled "Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity". This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis, independent of blood pressure, and proportionately to the severity of autonomous ...
What is the current status of trial NCT04519164?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2020-12-01. Estimated completion is 2025-09-17.
What interventions are being tested in trial NCT04519164?
The interventions under investigation include: Eplerenone (DRUG), Chlorthalidone with potassium chloride (DRUG).
Who is sponsoring clinical trial NCT04519164?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.